The US Food and Drug Administration has approved a new oral antibiotic for treatment of uncomplicated urinary tract ...

The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to ...

In 2021, the FDA rejected the oral antibiotic based on mixed data from another phase III trial and recommended that Iterum ...

A mild UTI may last days or under a week. These are sometimes called uncomplicated UTIs. Learn how long a complicated UTI ...

The treatment has been shown to be active against third generation cephalosporin-resistant Enterobacterales species. Orlynvah combines sulopenem etzadroxil, a penem antibacterial drug, and probenecid, ...

The FDA has approved Orlynvah, a new oral treatment for uncomplicated urinary tract infections (UTIs) in women who have limited options for effective antibiotic therapy.

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat certain types of bacterial ...

The US Food and Drug Administration (FDA) approved a new oral antibiotic to treat uncomplicated urinary tract infections ...

The FDA granted Priority Review to gepotidacin for the treatment of female adults and adolescents with uncomplicated UTI.

Orlynvah is the first oral penem approved in the U.S. and Iterum Therapeutics’ first FDA-approved product. CEO Corey Fishman ...

From today, Australian women in every state and territory can access treatment for uncomplicated urinary tract infections at a community pharmacy ...